Toronto Dominion Bank Has $12.02 Million Stock Holdings in ResMed Inc. (NYSE:RMD)

Toronto Dominion Bank increased its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 15.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 49,250 shares of the medical equipment provider's stock after acquiring an additional 6,476 shares during the period. Toronto Dominion Bank's holdings in ResMed were worth $12,023,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RMD. True Wealth Design LLC boosted its holdings in ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 110 shares in the last quarter. OFI Invest Asset Management bought a new position in shares of ResMed in the second quarter valued at approximately $32,000. Ashton Thomas Securities LLC acquired a new position in shares of ResMed in the 3rd quarter worth approximately $34,000. Financial Connections Group Inc. bought a new stake in ResMed during the 2nd quarter worth approximately $37,000. Finally, Blue Trust Inc. increased its holdings in ResMed by 182.7% during the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 137 shares in the last quarter. Institutional investors own 54.98% of the company's stock.

Analyst Ratings Changes

RMD has been the topic of a number of research analyst reports. Robert W. Baird increased their price objective on shares of ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Wolfe Research reissued an "underperform" rating and issued a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. Stifel Nicolaus started coverage on ResMed in a report on Friday. They set a "hold" rating and a $250.00 price objective on the stock. Bank of America lifted their target price on ResMed from $240.00 to $270.00 and gave the company a "buy" rating in a research note on Thursday, September 26th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $227.91.

ResMed Trading Down 1.6 %

Shares of RMD stock traded down $3.99 on Friday, reaching $238.52. The company had a trading volume of 580,589 shares, compared to its average volume of 1,019,118. The stock has a market cap of $35.01 billion, a PE ratio of 31.59, a PEG ratio of 1.78 and a beta of 0.68. The company has a 50-day moving average of $242.75 and a 200-day moving average of $227.59. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 12 month low of $164.12 and a 12 month high of $260.49.

ResMed (NYSE:RMD - Get Free Report) last posted its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the business posted $1.64 earnings per share. The business's revenue for the quarter was up 11.1% compared to the same quarter last year. On average, equities analysts forecast that ResMed Inc. will post 9.34 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th were issued a $0.53 dividend. The ex-dividend date was Thursday, November 7th. This represents a $2.12 annualized dividend and a dividend yield of 0.89%. ResMed's dividend payout ratio (DPR) is currently 28.08%.

Insider Transactions at ResMed

In related news, Director Witte Jan De sold 796 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the sale, the director now directly owns 6,723 shares of the company's stock, valued at approximately $1,672,749.63. The trade was a 10.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total value of $491,300.00. Following the transaction, the director now owns 81,218 shares of the company's stock, valued at approximately $19,951,201.70. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,725 shares of company stock valued at $11,253,448 over the last 90 days. 0.71% of the stock is owned by company insiders.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.